# A Safety and Efficacy Study of Tralokinumab in Adults With Asthma

> **NCT01402986** · PHASE2 · COMPLETED · sponsor: **MedImmune LLC** · enrollment: 689 (actual)

## Conditions studied

- Asthma

## Interventions

- **OTHER:** Placebo Q2W
- **BIOLOGICAL:** Tralokinumab 300 mg, Q2W
- **OTHER:** Placebo, Q2/4W
- **BIOLOGICAL:** Tralokinumab 300 mg, Q2/4W

## Key facts

- **NCT ID:** NCT01402986
- **Lead sponsor:** MedImmune LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-08
- **Primary completion:** 2013-06
- **Final completion:** 2014-02
- **Target enrollment:** 689 (ACTUAL)
- **Last updated:** 2017-04-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01402986

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01402986, "A Safety and Efficacy Study of Tralokinumab in Adults With Asthma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01402986. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*